• Cell Counting Kit-8 Plus: Rapid, Sensitive Proliferation Ass

  2026-07-07

  Cell Counting Kit-8 (CCK-8) Plus delivers rapid, highly sensitive measurement of cell viability and cytotoxicity, outperforming traditional tetrazolium salt assays. Its optimized WST-8 chemistry and broad detection range accelerate drug screening, proliferation, and mechanistic studies, empowering researchers to extract robust, quantitative data even from challenging models.

• AMD-070 Hydrochloride: Applied Workflows for CXCR4 Antagonis

  2026-07-07

  AMD-070 hydrochloride (Mavorixafor hydrochloride) delivers potent, selective CXCR4 antagonism for advanced modeling of cell migration, anti-HIV strategies, and rare immunodeficiency research. This article provides actionable protocols and troubleshooting insights, bridging genomic findings and practical assay optimization.

• PEGylated PLGA Microspheres for Controlled Corticosteroid Re

  2026-07-06

  This study introduces a PEGylated, hydrocortisone-17-butyrate-loaded poly(lactic-co-glycolic acid) (PLGA) microsphere system engineered for extended intra-articular corticosteroid delivery. By optimizing surface functionalization and release kinetics, the work advances strategies to improve bioavailability and mitigate burst release, with implications for safer, more effective autoimmune disease therapies.

• Translating CXCR4 Antagonism: Mavorixafor Hydrochloride’s Im

  2026-07-06

  Explore how Mavorixafor hydrochloride (AMD-070 hydrochloride), a potent and selective CXCR4 antagonist, is redefining translational research and rare disease modeling. This article examines the mechanistic, clinical, and workflow implications for scientists targeting the CXCR4/CXCL12 axis, spotlighting new evidence and best practices for experimental success.

• Ibrexafungerp and Caspofungin Against Candida auris: Insight

  2026-07-05

  The referenced study demonstrates that ibrexafungerp, a triterpenoid antifungal, is effective both in vitro and in vivo against fluconazole-resistant Candida auris, even when therapy is delayed. These findings benchmark ibrexafungerp's efficacy alongside caspofungin and underscore the need for expanded options in antifungal agent development and translational workflows.

• THZ1 and Covalent CDK7 Inhibition: Shaping Tomorrow’s Cancer

  2026-07-04

  This thought-leadership piece provides translational researchers with actionable insight into the mechanistic, strategic, and workflow dimensions of THZ1—a potent covalent CDK7 inhibitor. Integrating findings from advanced HIV-1 signaling research and the latest protocol-driven best practices, the article uniquely bridges conceptual and practical gaps, offering guidance on leveraging THZ1 for transformative progress in T-ALL and broader cancer biology.

• Hoechst 33258: Illuminating DNA Dynamics in Tumor Mechanobio

  2026-07-03

  Explore the advanced use of Hoechst 33258 as a bis-benzimide DNA stain for probing chromatin structure and cell cycle events in live and fixed tumor cells. This article goes beyond standard protocols, connecting fluorescence DNA staining to the latest insights in tumor cell mechanics and intercellular oncogene transfer.

• Iptacopan (LNP023): Applied Workflows for Complement Pathway

  2026-07-03

  Iptacopan (LNP023) delivers precise, reversible inhibition of complement factor B, revolutionizing research in alternative pathway-driven diseases. Its robust selectivity and oral bioavailability streamline both in vitro and in vivo workflows, empowering translational models and hemolysis assays with unparalleled specificity.

• Syringin Enhances Sunitinib Response in Renal Cell Carcinoma

  2026-07-02

  This study demonstrates that Syringin, a phenylpropanoid glycoside, inhibits renal cell carcinoma (RCC) cell proliferation and migration while promoting apoptosis by modulating the EGFR/PI3K/Akt pathway. The compound also sensitizes RCC cells to sunitinib, suggesting a novel combinatorial approach to overcoming drug resistance and improving targeted therapy efficacy.

• Spleen-Targeted Neoantigen mRNA Vaccine Drives ISG15+ CD8+ T

  2026-07-02

  Lin et al. introduce a spleen-targeted neoantigen mRNA vaccine that elicits robust antitumor immunity in hepatocellular carcinoma (HCC) by expanding a novel ISG15+ CD8+ T cell population and promoting tertiary lymphoid structure formation. This mechanistic advance highlights the role of targeted mRNA delivery and immune cell interactions in overcoming the traditionally immunotherapy-resistant TME of HCC.

• Patient-Derived 3D Spheroids: A Translational Model for Pros

  2026-07-01

  The reference study establishes patient-derived three-dimensional spheroid cultures from radical prostatectomy tissues as a robust in vitro model for organ-confined prostate cancer. This innovation enables long-term viability, recapitulates tumor heterogeneity, and provides a more accurate platform for preclinical drug testing and mechanistic research.

• Rotenone: Gold-Standard Mitochondrial Complex I Inhibitor Wo

  2026-07-01

  Rotenone is the benchmark mitochondrial Complex I inhibitor for modeling dysfunction, apoptosis, and ROS signaling in neurodegenerative and metabolic disease research. This article delivers robust experimental workflows, troubleshooting strategies, and practical insights for applied use, leveraging both new and established scientific findings.

• S Tag Peptide: Technical Guide for Protein Solubility & Dete

  2026-06-30

  S Tag Peptide (SKU A6007) enables improved solubility and reliable antibody-based detection of recombinant proteins, supporting efficient workflow design for protein expression and purification. It is not suitable for protocols requiring ethanol solubility, enzymatic activity from the tag, or long-term aqueous storage.

• CX-4945 (Silmitasertib): Redefining CK2 Inhibition in Viral

  2026-06-30

  Explore how CX-4945 (Silmitasertib) advances CK2 inhibition, bridging oncology and virology. Learn how this selective inhibitor empowers innovative research on apoptosis and cell cycle control.

• UK-5099 in Immunometabolism: Applied Protocols and Troublesh

  2026-06-29

  UK-5099 (PF-1005023) empowers immunometabolic research by selectively inhibiting the mitochondrial pyruvate carrier, enabling precise metabolic modulation in whole-blood and cellular assays. This guide delivers actionable workflows, advanced troubleshooting, and translational insights to maximize reproducibility and impact in mitochondrial metabolism research.

14699 records 1/980 page Next 12345 下5页 Last page